Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes

被引:39
作者
Harte, AL
McTernan, PG
McTernan, CL
Smith, SA
Barnett, AH
Kumar, S
机构
[1] Univ Birmingham, Dept Med, Div Med Sci, Birmingham, W Midlands, England
[2] Heartlands Hosp, Birmingham, W Midlands, England
[3] GlaxoSmithKline, Harlow, Essex, England
关键词
adipose tissue; insulin; PAI-1; rosiglitazone; t-PA;
D O I
10.1046/j.1463-1326.2003.00276.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to investigate the effect of insulin and an insulin-sensitizing agent, rosiglitazone (RSG), on the production of plasminogen-activator inhibitor-1 (PAI-1) in isolated subcutaneous abdominal adipocytes. Human tissue-type plasminogen activator (t-PA) was also measured to assess changes in overall thrombotic risk. Methods: The mean depot-specific expression of PAI-1 and t-PA mRNA (n = 42) in subcutaneous abdominal (n = 21), omental (n = 10) and thigh (n = 11) adipose tissue depots was examined. Furthermore, subcutaneous adipocytes were treated with insulin, RSG and insulin in combination with RSG (10(-8) M) for 48 h. Conditioned media were collected and enzyme-linked immunosorbent assays performed for PAI-1 and t-PA (n = 12) antigen. PAI-1 and t-PA mRNA levels were also assessed. Results: PAI-1 mRNA levels were significantly higher in subcutaneous and omental abdominal tissue than in thigh fat (p = 0.037 and p = 0.014). No change in t-PA mRNA expression between the adipose tissue depots was observed. Insulin stimulated PAI-1 protein secretion in a concentration-dependent manner in adipocytes (control: 68.3 +/- 1.2 ng/ml (s.e.m.); 10 nM insulin: 73.7 +/- 3.8 ng/mlup arrow; 100 nM insulin: 86.8 +/- 4.1 ng/mlup arrow**; 1000 nM insulin: 102.0 +/- 4.8 ng/mlup arrow***; **p < 0.01, ***p < 0.001). In contrast, insulin + RSG (10(-8) M) reduced PAI-1 production relative to insulin alone (***p < 0.001), whilst RSG alone reduced PAI-1 protein secretion in a concentration-dependent manner (RSG at 10(-10) M: 50.4 +/- 2.87 ng/ml down arrow***; RSG at 10(-5) M: 30.3 +/- 2.0 ng/ ml down arrow***; p < 0.001). No difference was observed between control and treatments for t-PA secretion (range 7-11 ng/ml). Conclusions: Insulin stimulated PAI-1 secretion, whilst RSG reduced both PAI-1 secretion alone and in combination with insulin. These data suggest that adipose tissue may contribute significantly to the elevated circulating PAI-1 in obesity. Therefore, RSG's effects on PAI-1 production in adipose tissue may contribute to the fall in circulating PAI-1 levels observed in patients receiving RSG therapy.
引用
收藏
页码:302 / 310
页数:9
相关论文
共 51 条
[31]  
LUNGREN CH, 1996, CIRCULATION, V93, P106
[32]   GROWTH OF MOUSE MELANOMA-CELLS IN HORMONE-SUPPLEMENTED, SERUM-FREE MEDIUM [J].
MATHER, JP ;
SATO, GH .
EXPERIMENTAL CELL RESEARCH, 1979, 120 (01) :191-200
[33]   Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women [J].
Mavri, A ;
Stegnar, M ;
Krebs, M ;
Sentocnik, JT ;
Geiger, M ;
Binder, BR .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (06) :1582-1587
[34]   Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss [J].
Mavri, A ;
Alessi, MC ;
Bastelica, D ;
Geel-Georgelin, O ;
Fina, F ;
Sentocnik, JT ;
Stegnar, M ;
Juhan-Vague, I .
DIABETOLOGIA, 2001, 44 (11) :2025-2031
[35]   FACTORS RESPONSIBLE FOR IMPAIRED FIBRINOLYSIS IN OBESE SUBJECTS AND NIDDM PATIENTS [J].
MCGILL, JB ;
SCHNEIDER, DJ ;
ARFKEN, CL ;
LUCORE, CL ;
SOBEL, BE .
DIABETES, 1994, 43 (01) :104-109
[36]   Resistin, central obesity, and type 2 diabetes [J].
McTernan, CL ;
McTernan, PG ;
Harte, AL ;
Levick, PL ;
Barnett, AH ;
Kumar, S .
LANCET, 2002, 359 (9300) :46-47
[37]   Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue [J].
McTernan, PG ;
Anwar, A ;
Eggo, MC ;
Barnett, AH ;
Stewart, PM ;
Kumar, S .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (07) :875-881
[38]   Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue [J].
Morange, PE ;
Aubert, J ;
Peiretti, F ;
Lijnen, HR ;
Vague, P ;
Verdier, M ;
Négrel, R ;
Juhan-Vague, I ;
Alessi, MC .
DIABETES, 1999, 48 (04) :890-895
[39]   Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians [J].
Nagi, DK ;
Tracy, R ;
Pratley, R .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (10) :1243-1247
[40]   AUGMENTATION OF THE SYNTHESIS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BY PRECURSORS OF INSULIN - A POTENTIAL RISK FACTOR FOR VASCULAR-DISEASE [J].
NORDT, TK ;
SCHNEIDER, DJ ;
SOBEL, BE .
CIRCULATION, 1994, 89 (01) :321-330